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1. Introduction 
Evidence-based medicine (EBM) is the process of systematically reviewing, appraising and 
using clinical research findings to aid the delivery of optimum clinical care to patients 
(Rosenberg and Donald, 1995). It is considered a new trend in both teaching medicine and 
supporting the clinical decisive process, answering the clinical questions. The basis of the 
evidence-based medicine comprises of analysing and interpreting current and reliable 
medical publications concerning certain subject (Laudański and Pierzyński., 2000).  
Evidence-based practice is “a process of care that takes the patient and his or her preferences 
and actions, the clinical setting including the resources available, and current and applicable 
scientific evidence, and knits the three together using the clinical expertise and training of 
the health-care providers.” (Haynes et al., 2002).  
Thus, EBP as illustrated in Figure (1) is the integration of clinical expertise, patient values, and 
the best research evidence into the decision making process for patient care. Clinical expertise 
refers to the clinician's cumulated experience, education and clinical skills. The patient 
brings to the encounter his or her own personal and unique concerns, expectations, and 
values. The best evidence is usually found in clinically relevant research that has been 
conducted using sound methodology (Sackett et al., 2000). 
Despite its ancient origins, evidence based medicine remains a relatively young discipline 
whose positive impacts are just beginning to be validated, and it will continue to evolve 
(Bennett et al., 1987; Shin et al., 1993). 
The aim of this chapter is to explore different aspects of evidence based medicine including 
background on its development, motives towards changing our attitudes in practice and 
how can evidence be extracted. The chapter will also highlight the major role of evidence 
based medicine in changing attitudes towards evidence based practice which ensures safety 
and efficiency of the health service provided, in the field of obstetrics and gynecology; a 
domain that has greatly participated in the establishment of evidence based medicine and 
evidence based practice. Many examples on how evidence based medicine has changed 
attitudes in practice will be displayed to demonstrate and emphasize this role. 
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Fig. 1. Evidence Based Practice (EBP) 
2. Why changing attitudes in practice 
Although clinical research is consistently producing new findings that may contribute to 
effective and efficient patient care, the findings of such research will not change population 
outcomes unless health services and health care professionals adopt them in practice 
(Grimshaw et al., 2001). 
However, the enormous volume of information that is published in an ever-increasing 
number of available medical journals constitute a major obstacle and a real challenge to 
obtaining reliable evidence for clinical practice from research. Over half a million papers on 
gynecology, infertility, pregnancy and obstetrics are published each year. To sift through 
these MEDLINE records, let alone the full papers that may be relevant, to identify those 
which should form the basis of clinical practice is an overwhelming and nearly impossible 
task. How, then, can busy clinicians have easy access to, and identify, the most appropriate 
information on which to base their clinical decisions? (Dodd and Crowther, 2006). 
The contribution of evidence-based medicine to improved patient outcomes in general 
practice is incontestable. Evidence based practice promotes practices that have better 
outcomes and are scientifically proven to be effective. It aims to eliminate unsound or risky 
practices, thus improving quality of care, providing best service to the patient and 
promoting patient safety.  
Actually, evidence based practice is one step toward making sure that each patient gets the 
best service possible. Furthermore, it helps physicians to keep knowledge up to date and 
supplements clinical judgment; very vital benefit especially in the light of the rapidly 
growing literature and medical advances. 
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3. Evidence based and experience oriented practice  
Clinical medicine is currently in transition from experience-oriented practice to an evidence-
based one which requires the best available evidence that answers our clinical questions for 
better safety and efficacy. However, there is a balance, and even tension, between evidence 
and clinical expertise: 
"Without clinical expertise, practice risks becoming tyrannized by external evidence, for 
even excellent external evidence may be inapplicable to or inappropriate for an individual 
patient. Without current best external evidence, practice risks becoming rapidly out of date, 
to the detriment of patients." Good doctors use both individual clinical expertise and the 
best available external evidence, and neither alone is enough (Sackett et al., 1996). 
Evidence based medicine helps clinicians to integrate the best external clinical evidence 
from systematic research with individual clinical expertise to make effective decisions about 
patient treatment and care. 
Best available external clinical evidence means clinically relevant research, often from the basic 
sciences of medicine, but especially from patient centred clinical research into the accuracy and 
precision of diagnostic tests, the power of prognostic markers, and the efficacy and safety of 
therapeutic, rehabilitative, and preventive regimens.  
External clinical evidence can inform, but can never replace, individual clinical expertise, and 
it is this expertise that decides whether the external evidence applies to the individual patient 
at all and, if so, how it should be integrated into a clinical decision (Sackett et al., 1996).  
4. How can evidence be extracted? 
The best evidence is usually found in clinically relevant research that has been conducted 
using sound methodology (Sackett et al., 2000). EBM is not restricted to randomized trials 
and meta-analyses. Actually, it involves tracking down the best external evidence with 
which to answer our clinical questions.  
Thus, to find out about the accuracy of a diagnostic test, we need to find proper cross-
sectional studies of patients clinically suspected of harboring the relevant disorder, not a 
randomized trial while for a question about prognosis, we need proper follow-up studies (i.e. 
prospective cohort studies) of patients assembled at a uniform, early point in the clinical 
course of their disease. And, sometimes, the evidence we need will come from the basic 
sciences, such as genetics or immunology. 
It is when asking questions about therapy that we should try to avoid the non-experimental 
approaches, because these routinely lead to false-positive conclusions about efficacy. 
Because the randomized trial, and especially the systematic review of several randomized 
trials, is so much more likely to inform us and so much less likely to mislead us, it has 
become the "gold standard" for judging whether a treatment does more good than harm 
(Sackett et al., 1996). 
5. Development of evidence based practice in obstetrics 
Although the term ‘evidence-based medicine’ was first used by Gordon Guyatt of McMaster 
University, Canada, in 1990, (Guyatt and Rennie, 2002) the development of evidence-based 
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practice in obstetrics began in the early 1970s. Archie Cochrane, in his now well-known 
writings (Cochrane, 1972), awarded the ‘wooden spoon’ to obstetricians for having made the 
poorest use of randomized controlled trials, and having widely incorporated changes into 
clinical practice without appropriate evaluation(Cochrane, 1972).  
Such observation inspired Iain Chalmers in 1974 to start the enormous task of collecting all 
randomized controlled trials related to the field of perinatal medicine. More than 3000 trials 
conducted between 1940 and 1984 were identified. This collection was first published in 
1985 as the Oxford Database of Perinatal Trials (ODPT) (Chlamers et al., 1986). In 1989, the 
first comprehensive synthesis of evidence for pregnancy care, entitled "Effective Care in 
Pregnancy and Childbirth" (ECPC), was published; it included systematic reviews of the 
identified randomized trials (Enkin et al., 1989).  
This two-volume book was condensed into the paperback "A Guide to Effective Care in 
Pregnancy and Childbirth (GECPC)" summarizing the available evidence on the effects of 
pregnancy care, and categorizing care practices into those with evidence of known benefit, 
those of uncertain benefit, and those of known harm (Enkin et al., 1989). All of these early 
pregnancy and childbirth initiatives were important forerunners to the Cochrane 
Collaboration (The Cochrane Library, 2005). 
6. Examples for how evidence based medicine changed practices in 
obstetrics and gynecology 
We will be displaying in the coming section many practical examples elaborating the great 
noticeable role of evidence based medicine in shifting the practices in obstetrics and 
gynecology towards better safety and higher efficacy and in eliminating risky unsafe 
practices. Evidence based medicine has changed attitudes towards interventions, 
therapeutics and diagnostics.  
6.1 Changing attitudes towards interventions (evidence based interventions)  
What matters in health care is identifying and using interventions that have been shown by 
strong research evidence to achieve the best outcomes within available resources for 
everyone (Fletcher and Lancet, 1999). Examples for such interventions will be discussed. 
6.1.1 The term breech trial 
Among most issues in the field of obstetrics that have been very controversial is the breech 
delivery. Approximately 4% of all infants are in breech presentation. Delivery in this 
position is more difficult, with increased risk of complications to the fetus such as umbilical 
cord prolapse, hypoxia, and fetal injury. 
Despite increased risks, breech deliveries are usually accomplished without complications 
and without the need for ‘expert assistance’ from an experienced, trained clinician or 
midwife. However, in the event that expert assistance is needed but not obtained, 
permanent damage can occur during breech births because of the lack of appropriate and 
well-timed actions by the birth attendant. 
Historically, vaginal breech deliveries were considered the norm until 1959, when routine 
cesarean delivery was shown to reduce perinatal mortality and morbidity (Wright, 1959). 
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While there was a general belief that planned cesarean delivery was better than planned 
vaginal delivery for breech deliveries, evidence was inconclusive because most studies were 
observational, two small RCTs showed no difference, and evidence suggested that 
improved neonatal outcomes might occur at the expense of poorer maternal outcomes. 
The Term Breech trial, a multi-center trial across 121 centers in 26 countries randomizing 
2088 women to ‘planned cesarean delivery’ or ‘planned vaginal’ deliveries (1997 – 2000). The 
trial found during interim analyses that cesarean delivery was associated with a reduced 
risk of perinatal morbidity and mortality. The term breech trial had an immediate dramatic 
impact on the management of term breech deliveries with policies changed in accordance 
with the trials findings. Rapid change in clinical practice occurred in many locations, 
although not universally, as some desired more evidence and others were reticent to accept 
the trials results as conclusive (Hannah et al., 2000). 
Several comparison studies showed alteration of clinical practice via examining rates of 
vaginal breech delivery versus cesarean delivery in various countries (e.g., New Zealand, 
Australia) (Kaushik and Gudgeon, 2003). 
6.1.2 Examples of other obstetrical interventions 
There was widespread variation in clinical practice in areas such as the role of external 
cephalic version (ECV) for breech presentation (effective in reducing the need for caesarean 
delivery), the use of prophylactic antibiotics at caesarean delivery (effective in reducing 
maternal puerperal sepsis), the use of antenatal corticosteroids for fetal lung maturation 
(effective in reducing the risk of neonatal respiratory disease and mortality in infants born 
preterm), the use of vacuum-assisted vaginal births (effective in reducing maternal vaginal 
and perineal trauma), and selective versus routine use of episiotomy (effective in reducing 
maternal perineal trauma).  
The systematic reviews first published in Effective Care in Pregnancy and Childbirth 
(ECPC) and The Oxford Database of Perinatal Trials (ODPT), and by the Cochrane 
Collaboration Pregnancy and Childbirth review group, summarized the best available 
evidence at the time, indicating benefit for all of these interventions. For some of these 
interventions, clinical practice has indeed changed.  
Prenatal corticosteroids are now widely prescribed for women at risk of preterm birth, with 
82% of mothers of infants born at less than 34 weeks’ gestation admitted to the neonatal 
intensive care unit in Australia, having been administered corticosteroids prior to birth 
(Donoghue et al., 2002). The uptake of ECV for breech presentation at term has been less 
successful, with only 67% of obstetricians surveyed in Australia and New Zealand offering 
ECV (Phipps et al., 2003). 
6.1.3 The obstetrical outcomes after conservative treatment of intraepithelial 
neoplasia or early invasive lesions 
With the establishment of effective screening programmes for cancer cervix, women are 
more commonly diagnosed early with preinvasive lesions and microinvasive cervical 
cancers which make younger women with such lesions candidate for conservative treatment 
for the sake of preservation of the potential for childbearing.  
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However, proper counseling of those young women on the effect of such conservative 
treatment on the obstetrical outcome has been problematic and inadequate till the 
emergence of an important meta-analysis performed by Kyrgiou et al in 2006 in which the 
authors have investigated the obstetric outcomes in women who underwent excisional 
procedures in the cervix (Kyrgiou et al., 2006). 
In this meta-anlaysis, a total of 27 studies were included. The authors exhibited that cold 
knife cervical conisation was significantly associated with preterm delivery, low birth 
weight and cesarean delivery; similarly Large Loop Excision of the Transformation Zone 
(LLETZ) was associated with preterm delivery, low birth weight and premature rupture of 
the membranes. Similar but marginally non-significant adverse effects were recorded for 
laser conisation. But the investigators did not detect significantly increased risks for 
obstetric outcomes after laser ablation. 
It was concluded that all the excisional procedures used to treat cervical intraepithelial 
neoplasia present similar pregnancy-related morbidity without apparent neonatal 
morbidity. This study changed the future attitude of gynecologists  towards women with 
abnormal cervical lesions and alerted the physicians to be more cautious for future 
treatment options. This study also provided clinicians with evidence base to counsel women 
appropriately (Kyrgiou et al., 2006). 
6.1.4 Preimplantation genetic screening for aneuploidies in IVF/ICSI 
Despite the great advances that have taken place in the field of in vitro fertilization (IVF) 
since its introduction in 1978 with the achievement of considerable success rates in almost 
all causes of infertility, still many women fail to become pregnant in spite of repeated 
transfers of apparently morphologically normal embryos.  
Among the highly accused causes for this repeated failure is the inherent abnormal 
chromosomal make-up of the embryos (i.e. embryonic aneuploidy) (Wilton, 2002). Other 
causes responsible for the pregnancy failure are the poor endometrial receptivity and the 
inefficiency of the embryo transfer techniques (Mansour and Aboulghar, 2002).  
Many of the chromosome abnormalities observed in human embryos will cause the embryos 
to die early in development, sometimes even before implantation, or before term pregnancy 
can be reached. 
Patient populations with certain characteristics (e.g. advanced maternal age, recurrent 
implantation failure , repeated miscarriages, patients undergoing testicular sperm extraction 
(TESE) and intracytoplasmic sperm injection (ICSI) have been considered at higher risk of 
producing aneuploid embryos (Kahraman et al., 2004; Munne et al., 2004; Gianaroli et al., 
2005) which would die around the time of implantation and therefore result in no 
established pregnancy (Munne et al., 2003; Caglar et al., 2005). 
In recent years, these observations of significant incidences of aneuploidy in early human 
embryos has led to the expansion of preimplantation genetic diagnosis techniques for 
aneuploidies (PGD-AS) to patients who are considered to have a poor prognosis of reaching 
a full-term pregnancy (Sermon et al., 2005). 
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Embryo morphology alone cannot be used to predict euploidy since many good quality 
embryos have been found to be aneuploid (Delhanty et al., 1997; Harper et al., 1995; Magli et 
al., 2001), thus genetic diagnosis is required to detect aneuploid embryos. 
Two main techniques namely; fluorescent in situ hybridization (FISH) for multiple 
chromosomes and polymerase chain reaction (PCR), are used to document a high frequency 
of chromosomal errors and aneuploidy in human preimplantation embryos. These 
techniques enable the selection of chromosomally normal embryos that are more likely to 
implant.  
PGD-AS is commonly also known as preimplantation genetic screening (PGS), with both 
terms used interchangeably. PGS needs to be differentiated from preimplantation genetic 
diagnosis (PGD). While the technology used in both techniques is almost identical, PGS and 
PGD differ mainly in their indications. PGD aims to prevent the birth of affected children in 
couples with a high risk of transmitting specific genetic disorders, whether numerical or 
structural in nature. PGS, on the other hand, aims to improve pregnancy rates in infertile 
couples undergoing IVF/ICSI treatment, and who do not have any chromosomal aberrations. 
PGS allows the detection of aneuploidy before the step of embryo transfer. Aneuploid 
embryos could be screened out and only euploid ones transferred, thus theoretically 
increasing the chance of pregnancy and reducing the chance of miscarriage. 
A recent systematic review and meta-analysis by Abou-Setta et al., in 2011 aimed to 
evaluate whether PGS can improve the clinical outcomes of IVF/ICSI compared with no 
intervention. There was no significant difference in live birth rates following PGS compared 
with no PGS (R.R = 0.79, 95% CI: 0.54 to 1.15; p = 0.22; I2 = 65.74%, 95% uCI: 10.51% to 
86.89%) (Figure 2). As well, there was no significant difference in clinical pregnancy rate 
following PGS compared with no PGS (R.R = 0.89, 95% CI: 0.67 to 1.17; p = 0.40; I2 = 62.00%, 
95% uCI: 1.70% to 76.66%) (Figure 3). 
 
Fig. 2. Forest plot of comparison: PGS vs Control Live birth rate 
The results of this systematic review showed that until today, there was no enough evidence 
in the literature to give a conclusive decision on the value of PGS for patients undergoing 
IVF/ICSI. Currently with the evidence at hand, PGS seems to have no impact on improving 
live birth rate (Figure 2) and the clinical pregnancy rate (Figure 3) in patients undergoing 
IVF/ICSI. In fact, many of the trials were not completed and were stopped early because of 
the ineffectiveness of the intervention (Abou-setta et al., 2011).  
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Fig. 3. Forest plot of comparison: PGS Vs Control Clinical pregnancy rate 
6.2 Changing attitudes towards therapeutics (evidence based therapeutics)  
The advances in therapeutics are tremendous with many novel drugs and therapies 
manufactured and developed every day with the emergence of new strategies and 
mechanisms of actions making the selection of the best effective therapy a difficult and 
challenging task. Evaluation of the superiority of a particular therapy based on a single trial 
is inadequate and deficient. Hence, for evaluation to be better and adequate, it should be 
served by a comprehensive and systematic review of all existing data sets. We will display 
examples for some therapeutics that have been evaluated in an evidence based approach, 
resulting in changing attitudes towards their use. 
6.2.1 Hormone Replacement Therapy: WHI study 
Hormone replacement therapy, (HRT) involves the replacement of the depleted hormone 
levels in menopausal women by the administration of synthetic estrogen with or without 
progestogen with the aim to alleviate symptoms of menopause.  
Despite the potential health benefits that were expected from the use of HRT, many risks 
and complications have been associated with its use. Although observational studies 
suggested protective effects on heart disease (Stampfer et al., 1991), osteoporosis (Lindsay et 
al., 1976), and even Alzheimer's disease (Henderson et al., 1994), recent clinical trials have 
questioned some of these benefits. Till now, the debate regarding the risk-benefit ratio of 
hormone replacement therapy has not been completely resolved. 
However, in July 2002, the Women’s Health Initiative (WHI), - a large, multicentric clinical 
trial by the National Heart, Lung and Blood Institute (NHLBI) and other units of National 
Institute of Health (NIH) – reported that hormone replacement therapy actually posed more 
health risks than benefits (Rossouw et al., 2002).  
This was the turning point in HRT, as the number of health hazards attributed to HRT 
grew, practitioners discontinued routine prescriptions for this once a time very popular and 
rampant treatment modality and HRT use substantially decreased in the general population 
(Dorval et al., 2007, Hersh et al., 2004, Majumdar et al., 2004). 
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The results of this study provide the best evidence available at present on HRT for 
prevention of heart disease, and indicate that combined HRT is not indicated for this 
purpose in the studied population, thus contradicting the reported beneficial effects of HRT 
on coronary heart disease (CHD) in previous observational studies (Rossouw et al., 2002). 
6.2.2 Inudction of ovulation in patients with polycystic ovary syndrome  
Polycystic ovary syndrome has an estimated prevalence of 4-8 % in reproductive-aged 
women (Knochenhauer et al., 1998; Asuncion et al., 2000). It is the most common cause of 
oligoanovulatory infertility (Hull, 1987). Ovulation in these cases has been suggested to be 
induced by the use of clomiphene citrate or insulin sensitizer or combination of both. 
Metformin as an insulin sensitizer improves peripheral insulin sensitivity by decreasing 
glucose production by the liver and increasing the sensitivity of target tissues to insulin. 
Metformin was also found to reduce levels of androgens in both lean and obese women, 
leading to increased rates of spontaneous ovulation (Batukan et al., 2001; Haas et al., 2003; 
Essah et al., 2006). 
It has been demonstrated by a number of studies that up to 40 % of anovulatory women 
with polycystic ovary syndrome will ovulate, and many will achieve pregnancy with 
metformin alone (Diamanti-Kandarakis et al., 1998; Neveu et al., 2007). 
Despite the postulated effectiveness of metformin in induction of ovulation in cases with 
polycystic ovary syndrome, randomised controlled trials conducted by Moll et al., 2006 and 
Legro et al., 2007 didn’t support these expectations.  
Moll et al., 2006 performed a randomised double blind clinical trial to compare the effect of 
clomiphene citrate plus metformin and clomiphene citrate plus placebo on induction of 
ovulation in women with newly diagnosed polycystic ovary syndrome. The authors 
recruited 228 women with polycystic ovary syndrome, of those, 111 women were allocated 
to clomiphene citrate plus metformin (metformin group) and 114 women were allocated to 
clomiphene citrate plus placebo (placebo group).  
The results of the study showed that the ovulation rate in the metformin group was 64% 
compared with 72% in the placebo group, a non-significant difference (risk difference − 8%, 
95% confidence interval − 20% to 4%). Hence, the authors concluded that metformin is not 
an effective addition to clomiphene citrate as the primary method of inducing ovulation in 
women with polycystic ovary syndrome. 
The above conclusion was also emphasized by another study performed by Legro et al. in 2007 
who conducted a randomized prospective study involving 626 infertile women with 
polycystic ovary syndrome. In this study, the authors found live-birth rates with clomiphene 
citrate alone were higher (22.5 %) than with metformin alone (7.2 %) (Legro et al., 2007).  
6.2.3 Metformin in prevention of ovarian hyperstimulation syndrome  
Ovarian hyperstimulation syndrome (OHSS) is considered to be the most serious 
complication of superovulation in IVF-embryo transfer. The syndrome can vary in 
presentation from mild to severe life threatening disease. Severe manifestations of OHSS 
may include massive fluid shifts, hemoconcentration or renal and liver dysfunction. The 
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syndrome may be ultimately complicated by thromboembolic events and adult respiratory 
distress syndrome (Rizk and Aboulghar, 1999).  
Several strategies have been suggested to prevent such life threatening complication of 
ovulation induction. Among the suggested strategies is the administration of metformin. A 
meta-analysis has indicated that the administration of metformin significantly prevents 
OHSS development in patients with polycystic ovary syndrome, a high risk group (Costello 
et al., 2006).  
The mechanism of action of metformin is not completely clear, but both reduction of ovarian 
reserve, as demonstrated by the reduction of anti-Müllerian hormone (AMH) values 
(Piltonen et al., 2005), and a reduced insulin dependent VEGF production (Tang et al., 2006), 
have been suggested. 
6.2.4 Changing attitudes in ovarian stimulation towards patient's safety  
Gonadotropin-releasing hormone agonists (GnRHa) were introduced in ovarian stimulation 
for IVF to suppress the premature surge of luteinizing hormone (LH).  
Various protocols have been suggested for controlled ovarian hyperstimulation in assisted 
reproduction, however, the long agonist protocol have been the standard protocol because 
of the associated increase in pregnancy rates.  
In this long agonist protocol, GnRHa is started either in the mid-luteal phase or in the early 
follicular phase of the preceding cycle and continued until pituitary desensitization has been 
achieved; usually after 2–3 weeks, at which point gonadotropin administration will be 
started (Al-Inany and Aboulghar, 2003).  
However, despite the increased pregnancy rates, the use of the GnRHa long protocols has 
been concurrently associated with an increase in the incidence of ovarian hyperstimulation 
syndrome (Rizk and Smitz, 1992).   
The fear from such serious and potentially life threatening complications has motivated 
researchers to study other alternative protocols that would achieve better safety with at least 
equivalent results, thus improving the outcome of IVF. Gonadotropin-releasing hormone 
antagonists have emerged as an alternative treatment for preventing premature LH surges 
during controlled ovarian hyperstimulation (Al-Inany et al., 2011). 
GnRH agonist and antagonist exert their effects through different mechanisms of action. 
GnRH agonists act by downregulation of pituitary GnRH receptors and desensitization of 
the gonadotropic cells, while GnRH antagonists act by directly and rapidly inhibiting 
gonadotropin release within several hours through competitive binding to pituitary GnRH 
receptors. This mechanism of action is dependent on the equilibrium between endogenous 
GnRH and the applied antagonist and is highly dose dependent in contrast to the agonists 
(Felberbaum et al., 1995).  
The competitive blockade of the receptors by GnRH antagonists results in immediate arrest 
of gonadotropin secretion; therefore, they can be given after starting gonadotropin 
administration. This will lead to dramatic reduction in the duration of treatment cycle as 
well as avoiding flare up and estrogen deprivation symptoms associated with GnRHa-
induced downregulation. 
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Cochrane reviews comparing GnRH antagonist to the more widely used long GnRH agonist 
protocols were published successively, with the first review published in 2001 (Al-Inany and 
Aboulghar, 2001), that was later updated in 2006 (Al-Inany et al., 2006) and recently updated 
again in 2011 (Al-Inany et al., 2011). The last updated review focused on patient-oriented 
value mainly safety and ongoing pregnancy/live birth rate.  
The earlier two versions of that review showed lower efficacy for GnRH antagonists while 
the most recent one showed lower pregnancy in antagonist but did not reach statistically 
significant level.  
According to the most recent review, nine trials reported live birth rates in 1515 women. 
There was no significant difference in live birth rates following GnRH antagonist compared 
with GnRH agonist (OR = 0.86, 95% CI = 0.69 to 1.08; p = 0.20; I2 = 0.00%, 95% CI = 0.00% to 
31.62%) (Figure 3).  
However, more importantly, there were a statistically highly significant lower incidence of 
OHSS in the GnRH antagonist group (Twenty-nine randomized controlled trials reported 
ovarian hyperstimulation rates in 5417 women, R.D = -0.03, 95% CI = -0.05 to -0.02; p < 
0.00001; I2 = 67,68%, 95% CI = 52.50% to 78.02%) (See Figure 4).  
Thus, there was a significant difference favouring GnRH antagonist compared with GnRH 
agonist. The incidence was reduced by 50% in antagonist group (1.91 vs 3.74%). The 
corresponding number needed to harm was 25 (95% CI: 19–36) with an absolute risk 
reduction of 4% (95% CI: 2.79–5.13).  
This means that for every 25 women undergoing downregulation by agonist, one more case 
of severe OHSS may be expected. In addition, the cancellation rate owing to high risk to 
develop OHSS was significantly higher in GnRHa group. This means that the difference 
would be highly significant if cancellation was not done (Al-Inany et al., 2011). 
6.2.5 For intrauterine insemination (IUI) timing: Which is the best; human chorionic 
gonadotropin administration or monitoring of LH surge?  
Kosmas et al., 2007 conducted a systematic review and meta-anlaysis to find out whether the 
timing of intrauterine insemination by the administration of hCG achieves better results 
than the monitoring of LH surge.  
Seven studies with 2,623 patients were involved in this meta-analysis, in which 1,461 
patients received hCG, and 1,162 had LH surge detection. When all studies were 
combined, patients who received hCG before IUI demonstrated lower clinical-pregnancy 
rates than did women who had IUI after spontaneous ovulation (odds ratio, 0.74; 95% 
confidence interval, 0.57–0.961).  
In subgroup analysis of studies that considered ovulatory dysfunction to be the infertility 
reason, the results favored women who received hCG. In contrast, across studies that 
reported male factor as the infertility reason, as well as across studies including women with 
unexplained infertility, results appeared to favor the LH surge detection approach. 
However, none of those subgroup analyses reached statistical significance (Kosmas et al., 
2007).  
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Fig. 4. Forest plot of comparison: GnRH antagonist Vs GnRH agonist live birth rate per 
women randomized 
6.3 Changing attitudes towards diagnostics (evidence based diagnosis)  
Evidence-based medicine has progressively developed as the standard approach for many 
diagnostic procedures. With the increasing varieties of investigating and diagnostic tools, 
evidence based medicine allows for the selection of the best diagnostic approach that would 
achieve the most reliable diagnosis with the least possible expenses, thus avoiding other less 
accurate and unnecessary diagnostic methods.  
6.3.1 Anti-Müllerian hormone  
Anti-Müllerian hormone (AMH) has become the ‘molecule of the moment’ in the field of 
Reproductive Endocrinology. Indeed, it is valuable as a means of increasing understanding 
of ovarian pathophysiology and for guiding clinical management across a broad range of 
conditions. 
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Fig. 5. GnRH antagonist vs GnRH agonist ovarian hyperstimulation per women randomised 
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In a cross-sectional study by La Marca et al., 2010, AMH was measured in 277 healthy 
females (aged 18–50 years) by commercial enzyme-linked immunosorbent assay. Serum 
AMH concentrations show a progressive decline with female ageing. The age-related 
changes in AMH were best fitted by a polynomial function. Mean AMH concentrations 
were not modified by past use of oral contraceptive and were independent of parity of 
women. Age-specific normative values for circulating AMH concentration were established. 
AMH concentrations seem to be independent of the reproductive history of the patient (La 
Marca et al., 2010). 
AMH plays a basic role as a prognostic marker in women undergoing ovarian stimulation 
protocols and can predict an excessive response to ovarian stimulation (Broer et al., 2010). 
7. Conclusions  
Evidence Based Medicine is currently changing our daily practice in obstetrics and 
gynecology towards achieving better health to women and mothers all over the world. The 
best evidence can be extracted from clinically relevant research that answers a clinical 
question using sound methodology.  
Our paradigms in the fields of diagnosis, interventions and therapeutics have exhibited 
some of the progress that has been performed throughout the last years. There is an 
increasing necessity for systematically reviewing, appraising and using clinical research 
findings to shift our practice towards an evidence based one. Evidence-based practice 
requires a clear view of the evidence combined with wise integration of this information 
with other knowledge and experience in clinical decision making. 
Evidence based medicine has been adopted, alongside health economics, and has been 
promoted as the gold standard tool for advancement and provision of health services in 
obstetrics and gynecology. Thus, a keen and sincere physician should be seeking evidence 
based medicine and integrating evidence based practice to deliver a higher level of health 
service to his patients.  
In a domain full of controversies as that of the obstetrics and gynecology, it is crucial to 
consider what the evidence says and exert every effort to integrate this evidence into 
practice as this will be the surest way that a patient will receive safe and effective up to date 
health service.  
Drawing examples on evidence based medicine is endless and can not be fulfilled 
completely in this context however, we aimed to draw the light on the role of evidence 
based medicine in changing attitudes in our routine daily practice by demonstrating some 
important examples that would emphasize that role.  
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